Splenomegaly Management in Myelofibrosis: Symptomatic and Asymptomatic Disease
Panelists discuss how managing asymptomatic splenomegaly in myelofibrosis requires a nuanced approach, balancing observation in low-risk patients with early intervention using Janus kinase (JAK) inhibitors in higher-risk cases, while emphasizing the …